Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022